Innovation Pharmaceuticals Inc (IPIX)

[TOB]

On this board there have been many comments about the superbugs and CTIX in the last several days. In the nicest way possible I simply wanted to point out that Brilacidin - so far as I know- would not kill those bacteria. This of course does not apply to what CTIX might have up its sleeve at Fox Chase etc- but these drugs are a long way out. Is that leading, or loaded? -TIAB

Yes, so far we have confirmation of Brilacidin efficacy against confirmed cases of 'superbug' MRSA in the MITT population. Other applications are more speculative. But the ABSSSI application is a big market already and Brilacidin looks poised to take the crown from Daptomycin.

i see that Klebsiella is also mentioned in a Polymedix article, in addition to E Coli. This in and of itself is sensational. Daptomycin and Vancomycin would have NO gm - activity for example. -TIAB

Not yet tested in humans. Some indications of broader use and even gram negative, but it looks like it is Brilacidin analogs such as CTIX-1278 and CTIX-1807 which show the most promise.

...
Initial research will focus on continuing the development of lead compounds active against CRE organisms, including CTIX 1807, which has shown robust activity against Klebsiella pneumoniae in a mouse tissue infection model.

...

Klebsiella pneumonia

In a thigh burden study of multi-drug resistant strain of Klebsiella pneumoniae in a mouse model, our defensin mimetic-compound CTIX-1278 was efficacious as compared to a carbapenem antibiotic that is widely used as a last line of defense against drug-resistant, Gram-negative bacteria. A second study is now being conducted at multiple dosing levels with various dosing parameters with the goal of increasing efficacy and further defining a treatment protocol for the compound.

... -CTIX

But "these drugs are a long way out" is relative, considering the QIDP potential to various accelerated tracks. Interesting that the CEO talks of having one of these analogs in the pipeline ready for the 2016 Olympics.

The killing ability of the compound against carbapenem-resistant Klebsiella pneumoniae [CRE] is astounding. Cellceutix is presently conducting safety testing and subsequently will determine if the drug is to be advanced to clinical trials. The Company continues to work with its collaborators at Fox Chase to develop a novel drug candidate as quickly as possible to be ready for the Rio 2016 Olympics where this may become a serious threat. -CTIX

Even if that time frame proves overly optimistic, it is quite realistic to expect Phase 1 and Phase 2 trials in the near future. Each stage of development is a potential share price support or boost.

Right now the real value is in Brilacidin, obviously, which has proven efficacy and safety for ABSSI, SA and MRSA. It is sure to progress to Phase 3 Clinical Trials, which should mean a higher share price, highly likely to attract a partnership, which should mean a higher share price, and with strong odds of approval which would certainly mean a much higher share price. Brilacidin could also prove efficacious for Oral Mucositis, Diabetic Foot infections/Ulcers, and Ocular and Otic applications. No doubt, Brilacidin is a near term winner, and a potential much larger winner.

Yes this pipeline of Brilacidin analogs has great promise as well. Certainly more speculative than Brilacidin for ABSSSI. Yet, with Brilacidin so far along, they are potential value added at this point, not priced into the current CTIX share price and not needed to have a significantly higher near term share price based solely on Brilacidin for ABSSSI.